123 related articles for article (PubMed ID: 8980393)
1. The cytotoxic action of four ammine/amine platinum(IV) dicarboxylates: a flow cytometric study.
Ormerod MG; Orr RM; O'Neill CF; Chwalinski T; Titley JC; Kelland LR; Harrap KR
Br J Cancer; 1996 Dec; 74(12):1935-43. PubMed ID: 8980393
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of novel ammine/amine platinum (IV) dicarboxylates in L1210 murine leukaemia cells sensitive and resistant to cisplatin, tetraplatin or carboplatin.
Orr RM; O'Neill CF; Nicolson MC; Barnard CF; Murrer BA; Giandomenico CM; Vollano JF; Harrap KR
Br J Cancer; 1994 Sep; 70(3):415-20. PubMed ID: 8080724
[TBL] [Abstract][Full Text] [Related]
3. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.
Kelland LR; Mistry P; Abel G; Loh SY; O'Neill CF; Murrer BA; Harrap KR
Cancer Res; 1992 Jul; 52(14):3857-64. PubMed ID: 1617660
[TBL] [Abstract][Full Text] [Related]
4. Apoptotic and non-apoptotic cell death induced by cis and trans analogues of a novel ammine(cyclohexylamine)dihydroxodichloroplatinum(IV) complex.
O'Neill CF; Ormerod MG; Robertson D; Titley JC; Cumber-Walsweer Y; Kelland LR
Br J Cancer; 1996 Oct; 74(7):1037-45. PubMed ID: 8855971
[TBL] [Abstract][Full Text] [Related]
5. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
Mellish KJ; Kelland LR; Harrap KR
Br J Cancer; 1993 Aug; 68(2):240-50. PubMed ID: 8347478
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro.
McKeage MJ; Abel G; Kelland LR; Harrap KR
Br J Cancer; 1994 Jan; 69(1):1-7. PubMed ID: 8286188
[TBL] [Abstract][Full Text] [Related]
7. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
O'Neill CF; Koberle B; Masters JR; Kelland LR
Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
[TBL] [Abstract][Full Text] [Related]
8. DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines.
Mellish KJ; Barnard CF; Murrer BA; Kelland LR
Int J Cancer; 1995 Sep; 62(6):717-23. PubMed ID: 7558420
[TBL] [Abstract][Full Text] [Related]
9. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
[TBL] [Abstract][Full Text] [Related]
10. Preclinical toxicology and tissue platinum distribution of novel oral antitumour platinum complexes: ammine/amine platinum(IV) dicarboxylates.
McKeage MJ; Morgan SE; Boxall FE; Murrer BA; Hard GC; Harrap KR
Cancer Chemother Pharmacol; 1994; 33(6):497-503. PubMed ID: 8137461
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines.
Mellish KJ; Kelland LR
Cancer Res; 1994 Dec; 54(23):6194-200. PubMed ID: 7954466
[TBL] [Abstract][Full Text] [Related]
12. Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels.
Raynaud FI; Odell DE; Kelland LR
Br J Cancer; 1996 Aug; 74(3):380-6. PubMed ID: 8695352
[TBL] [Abstract][Full Text] [Related]
13. Antitumor-activity of orally-administered ammine amine platinum (iv) dicarboxylate complexes against a panel of human ovarian-carcinoma xenografts.
Kelland L; Jones M; Gwynne J; Valenti M; Murrer B; Barnard C; Vollano J; Giandomenico C; Abrams M; Harrap K
Int J Oncol; 1993 Jun; 2(6):1043-8. PubMed ID: 21573668
[TBL] [Abstract][Full Text] [Related]
14. Axial ligands and alicyclic ring size modulate the activity and biochemical pharmacology of ammine/cycloalkylamine-platinum(IV) complexes in tumor cells resistant to cis-diamminedichloroplatinum(II) or trans-1R,2R-1S,2S-diaminocyclohexanetetrachloroplatinum(IV).
Yoshida M; Khokhar AR; Siddik ZH
Cancer Res; 1994 Sep; 54(17):4691-7. PubMed ID: 8062266
[TBL] [Abstract][Full Text] [Related]
15. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts.
Reardon JT; Vaisman A; Chaney SG; Sancar A
Cancer Res; 1999 Aug; 59(16):3968-71. PubMed ID: 10463593
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study.
Kurata T; Tamura T; Sasaki Y; Fujii H; Negoro S; Fukuoka M; Saijo N
Jpn J Clin Oncol; 2000 Sep; 30(9):377-84. PubMed ID: 11095134
[TBL] [Abstract][Full Text] [Related]
17. Tetravalent platinum complexes with ammine/amine carrier ligand configuration: circumvention of platinum resistance in vivo.
Siddik ZH; Thai G; Yoshida M; Zhang YP; Khokhar AR
Anticancer Drug Des; 1994 Dec; 9(6):495-509. PubMed ID: 7880375
[TBL] [Abstract][Full Text] [Related]
18. Influence of a novel platinum compound--cis-dichloro (dimethylsulphoxide) (1-beta-D-rybofuranosyl-1,2,4-triazolo-3-arboxyamide) platinum (II)--"Pt-rib-1"--on cell cycle and apoptosis in ClS91 and B16 mouse melanoma in vitro.
Drewa T; Olszewska-Słonina D; Woźniak A; Styczyński J; Drewa G; Szłyk E; Lakomska I; Kobe J; Czajkowski R
Acta Pol Pharm; 2004; 61(1):39-44. PubMed ID: 15259856
[TBL] [Abstract][Full Text] [Related]
19. Circumvention of platinum resistance: structure-activity relationship for homologous series of ammine/amine platinum(II) complexes in L1210 cell lines.
Yoshida M; Khokhar AR; Siddik ZH
Anticancer Drug Des; 1994 Oct; 9(5):425-34. PubMed ID: 7945726
[TBL] [Abstract][Full Text] [Related]
20. Biotransformation of the platinum drug JM216 following oral administration to cancer patients.
Raynaud FI; Mistry P; Donaghue A; Poon GK; Kelland LR; Barnard CF; Murrer BA; Harrap KR
Cancer Chemother Pharmacol; 1996; 38(2):155-62. PubMed ID: 8616906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
